Formulation: A solid
Formal Name: 7-fluoro-1,3-dihydro-3-methyl-1-(1-methylethyl)-8-[6-[3-(1-piperidinyl)propoxy]-3-pyridinyl]-2H-imidazo[4,5-c]quinolin-2-one
Purity: ≥98%
Formula Markup: C27H32FN5O2
Formula Weight: 477,6
Shelf life (days): 1460
CAS Number: 2089288-03-7
Notes: AZD 1390 is an inhibitor of Ataxia-telangiectasia mutated (ATM) kinase (IC50 = 0.78 nM).{51238} It is selective for ATM over Ataxia-telangiectasia and Rad3-related protein/kinase (ATR), PI3K, mammalian target of rapamycin (mTOR), and DNA protein kinase (DNA-PK; IC50s = >30, >12, >16, and >29.9 µM, respectively). AZD 1390 (10 nM) sensitizes glioma cells expressing mutant, but not wild-type, p53 to ionizing radiation. Oral administration of AZD 1390 (20 mg/kg twice daily), in combination with radiation, reduces the growth of brain metastases and increases survival in an NCI H2228 lung carcinoma mouse xenograft model.
English
Deutsch
